American Century Companies Inc. acquired a new stake in Vericel Corp (NASDAQ:VCEL) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 130,760 shares of the biotechnology company’s stock, valued at approximately $2,275,000. American Century Companies Inc. owned 0.30% of Vericel as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Perceptive Advisors LLC lifted its holdings in shares of Vericel by 3.2% during the 4th quarter. Perceptive Advisors LLC now owns 28,090 shares of the biotechnology company’s stock worth $488,000 after acquiring an additional 879 shares during the period. Legal & General Group Plc lifted its holdings in shares of Vericel by 17.1% during the 3rd quarter. Legal & General Group Plc now owns 6,443 shares of the biotechnology company’s stock worth $91,000 after acquiring an additional 943 shares during the period. Meeder Asset Management Inc. lifted its holdings in shares of Vericel by 28.7% during the 4th quarter. Meeder Asset Management Inc. now owns 5,765 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 1,284 shares during the period. Doyle Wealth Management bought a new stake in shares of Vericel during the 4th quarter worth approximately $35,000. Finally, Commonwealth Equity Services LLC lifted its holdings in shares of Vericel by 10.3% during the 4th quarter. Commonwealth Equity Services LLC now owns 22,625 shares of the biotechnology company’s stock worth $393,000 after acquiring an additional 2,114 shares during the period. 83.30% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have recently weighed in on VCEL shares. Oppenheimer started coverage on shares of Vericel in a report on Tuesday, January 29th. They set an “outperform” rating and a $23.00 price target for the company. Zacks Investment Research downgraded shares of Vericel from a “buy” rating to a “hold” rating in a report on Friday, March 1st. BidaskClub downgraded shares of Vericel from a “buy” rating to a “hold” rating in a report on Friday, March 15th. Finally, Needham & Company LLC downgraded shares of Vericel from a “buy” rating to a “hold” rating and set a $17.92 price target for the company. in a report on Thursday, February 28th. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Vericel has an average rating of “Buy” and a consensus target price of $20.73.
Vericel (NASDAQ:VCEL) last issued its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported $0.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.05 by $0.06. The business had revenue of $31.34 million during the quarter, compared to the consensus estimate of $28.69 million. Vericel had a negative net margin of 8.96% and a negative return on equity of 7.58%. The firm’s revenue was up 34.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.01 EPS. On average, research analysts forecast that Vericel Corp will post 0.07 earnings per share for the current year.
In related news, CFO Gerard J. Michel sold 10,000 shares of the stock in a transaction that occurred on Monday, February 11th. The shares were sold at an average price of $17.09, for a total value of $170,900.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Gerard J. Michel sold 15,625 shares of the stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $17.64, for a total transaction of $275,625.00. Following the completion of the transaction, the chief financial officer now directly owns 127,047 shares of the company’s stock, valued at approximately $2,241,109.08. The disclosure for this sale can be found here. In the last three months, insiders sold 43,125 shares of company stock valued at $781,875. 4.50% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This article was first published by Community Financial News and is owned by of Community Financial News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.com-unik.info/2019/04/17/american-century-companies-inc-takes-position-in-vericel-corp-vcel.html.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
See Also: Different Options Trading Strategies
Want to see what other hedge funds are holding VCEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vericel Corp (NASDAQ:VCEL).
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.